Orientador: Luiz Carlos de Mattos / Banca: Antonio Carlos Pires / Banca: Haroldo Wilson Moreira / Resumo: O diabetes melito (DM) é um grupo heterogêneo de alterações metabólicas, caracterizado por hiperglicemia crônica, com alterações do metabolismo de carboidratos, ácidos graxos e proteínas. O diabetes melito tipo 2 (DMT2) é a forma mais comum dessa doença, acomentendo aproximadamente 90% dos indivíduos que apresentam DM. Caracteriza-se principalmente por modificações da ação e secreção de insulina, embora sua etiologia, genética e fisiopatologia específicas ainda não estejam completamente determinadas. Os pacientes com DMT2 apresentam maior risco de desenvolvimento de complicações macro e microvasculares. Estudos revelaram que a enzima conversora de angiotensina (ECA) e a adenosina deaminase (ADA) podem estar relacionadas ao desenvolvimento de DMT2 ou de suas complicações. Com base nesses dados, foram estudados os polimorfismos I/D do gene ECA e TaqI do gene ADA em 162 indivíduos com DMT2, e 160 indivíduos saudáveis. Segundo a Associação Americana de Diabetes, os indivíduos diabéticos que apresentam HDLc abaixo de 40mg/dl ou LDLc acima de 100 mg/dl ou triglicerídeos acima de 150 mg/dl apresentam maior risco de desenvolvimento de doenças cardiovasculares. Por isso, foram selecionados 81 indivíduos com essas características para compor o grupo de estudo de pacientes diabéticos com "risco de doença cardiovascular". Os polimorfismos foram avaliados por PCR e PCR-RFLP para os genes da ECA e ADA respectivamente. As frequências obtidas para o polimorfismo do gene ECA foram: pacientes diabéticos: I/I (19,1%); I/D (52,5%); D/D (28,4%); grupo controle I/I (12,5%); I/D (55,6%); D/D (31,9%) e grupo de diabéticos com riscos de doença cardiovascular I/I (16%); I/D (59,3%); D/D (24,7%). E para o gene ADA: em pacientes diabéticos ADA*1/*1 (89,31%); ADA*1/*2 (10,06%); ADA*2/*2 (0,63%); grupo controle ADA*1/*1 (91,25%); ADA*1/*2 (7,50%); ADA*2/*2 (1,25%); pacientes... (Resumo completo, clicar acesso eletrônico abaixo) / Abstract: Diabetes mellitus (DM) is a heterogeneous group of metabolic disorders characterized by chronic hyperglycemia, with changes in the carbohydrates, fatty acids and proteins metabolism. Diabetes mellitus type 2 (DMT2) is the most common form of this disease, that affect approximately 90% of people who have DM. It is characterized mainly by changes in the action and insulin secretion, although the etiology, genetics and specific pathophysiology of the disease is not yet completely determined. DMT2 patients have a higher risk of developing macro and microvascular complications. Studies have shown that angiotensin-converting enzyme (ACE) and adenosine deaminase (ADA) may be related to the development of DMT2 or its complications. Based on these data, we studied the polymorphisms I / D of the ACE gene and the polymorphism TaqI in the ADA gene, in 162 patients with DMT2, and 160 blood donors. According to the American Diabetes Association, people with diabetes who have HDL-C below 40 mg / dL or LDL-C above 100 mg / dl or triglycerides above 150 mg / dl are at increased risk of developing cardiovascular disease. Therefore, we selected 81 individuals with these characteristics to compose the study group of diabetic patients named "risk of cardiovascular disease ". The polymorphisms are evaluated by PCR for ACE gene and PCR-RFLP for the ADA Gene. The frequencies obtained for the ACE gene polymorphism were: diabetic patients: I / I (19.1%), I / D (52.5%) and D / D (28.4%), control group: I / I ( 12.5%) I / D (55.6%) and D / D (31.9%) and group of patients with cardiovascular disease risk: I / I (16%) I / D (59.3% ), D / D (24.7%). And for the ADA gene polymorphism: in diabetic patients: ADA * 1 / * 1 (89.31%); ADA * 1 / * 2 (10.06%), ADA * 2 / * 2 (0.63%); control group: ADA * 1 / * 1 (91.25%); ADA * 1 / * 2 (7.50%); ADA * 2 / * 2 (1.25%), and patients with cardiovascular risk:... (Complete abstract click electronic access below) / Mestre

A utilização da cintilografia de perfusão miocárdica (CPM) estava limitada a pacientes que podiam realizar algum tipo de exercício, para ampliarmos a disponibilidade clínica da CPM, vários protocolos com estresses farmacológicos foram desenvolvidos. A adenosina fármaco amplamente utilizado, potente vasodilatador coronariano, apresenta uma importante interação com outras substâncias que anatagonizam seus efeitos, o dipiridamol, alimentos com cafeína e derivados de xantinas. O tempo de suspensão de cafeína da dieta para o uso exógeno da adenosina na realização da CPM ainda não está definido. Para testar essa hipótese avaliamos a influência da abstinência de cafeína em 24h, 12h e 1h, através de sua dosagem sérica, antes do estresse farmacológico com adenosina e sua possível repercussão nas imagens da CPM e o efeito vasodilatador no sistema cardiovascular. Definimos como objetivo primário: comparar a presença e a extensão dos defeitos reversíveis da CPM verificados em pacientes com abstinência de café por 24 horas (E1) com as imagens da randomização com 1 hora e 12 horas (E2) sem cafeína e como objetivos secundários: avaliar a presença e intensidade dos paraefeitos, comportamento da frequência cardíaca e da pressão arterial sistêmica. Foram submetidos ao estresse farmacológico com adenosina 194 pacientes para a realização da CPM, dos quais 43 pacientes preencheram os critérios para a randomização (defeitos perfusionais transitórios na CPM com adenosina). Excluímos seis pacientes (13,9%), três (6,9%) se recusaram a realizar a fase da randomização e os outros três (6,9%) nos quais não houve consenso entre os observadores em relação aos defeitos de perfusionais transitórios. A média de idade dos 37 pacientes analisados foi de 61,4 ± 8,3 anos, sendo 21 pacientes do sexo masculino (56,8%). Na avaliação das imagens da CPM, não houve diferença entre as imagens obtidas no grupo E1 comparadas as imagens de 1 (2,0 ± 1,5) hora ou 12 (12,6 ± 3,1) horas sem cafeína (E2). As médias de cafeína sérica encontradas foram de 0,14 ± 0,17 mg/l no grupo E1 do E2 de 1 hora e 0,13 ± 0,24 mg/l no grupo E1 do E2 de 12 horas, na randomização de 1 hora de 1,97± 0,83 mg/l e de 12 horas de 1,51 ± 1,46 mg/l (E1 vs. E2: p < 0,001). Em relação à presença dos paraefeitos, ocorreram em 31 pacientes (83,7%) e os mais freqüentes foram: dor precordial atípica, cansaço e dor em região cervical. Não foram observadas diferenças em relação às freqüências absolutas e relativas na ocorrência de paraefeitos entre os grupos. A intensidade dos paraefeitos foi verificada através de análise subjetiva comparando os sintomas em relação aos exames. Notou-se que em 22 pacientes (59,4%), caracterizaram o estudo randomizado como bem melhor, ou melhor, que o de 24 horas. A pressão arterial sistêmica e a freqüência cardíaca também não apresentaram diferenças entre os grupos. Conclusões: Os resultados permitem inferir que o uso da cafeína ingerida 2 horas antes da realização da CPM com adenosina foi eficaz e segura, pois apesar da modificação da resposta vasodilatadora máxima alcançada, traduzida pela melhor tolerância do exame realizado com menos tempo de ausência de cafeína na dieta, não modificou o resultado final da CPM / Myocardial perfusion imaging (MPI) in the past was only available to patients who were able to perform some type of exercise. Many protocols were developed with pharmacologic stress in order to enlarge the clinical availability of myocardial perfusion imaging (MPI). Adenosine is widely used and a potent coronary vasodilator, exhibits a significant interaction with other substances which antagonize its effects, such as dipyridamole, food products containing caffeine and xanthine derivatives. We found no clear consensus as to the time between caffeine ingestion and a cardiovascular adenosine stress test. To test this hypothesis we evaluated the influence of 24-hour, 12-hour and 1-hour caffeine abstinence, by assessing plasma caffeine levels before adenosine pharmacological stress, the possible repercussions on MPI images and vasodilatory effects on the cardiovascular system. The primary endpoint was to compare the presence and extent of reversible myocardial perfusion defects found in patients with 24-hour abstinence from coffee (E1), with images from patients randomized to 1-hour or 12-hour caffeine abstinence (E2). As secondary endpoints we evaluated the presence and intensity of paraeffects, as well as heart rate and systemic arterial blood pressure behavior. For this purpose, 194 patients underwent pharmacological stress with adenosine for MPI, 43 of whom fulfilled criteria for randomization (patients with transient perfusion defects detected on adenosine MPI). Six patients were excluded (13.9%), three patients (6.9%) who refused to undergo randomization, and other three (6.9%) in whom the observers could not reach consensus regarding transient perfusion defects. Mean age for the 37 patients analyzed was 61.4 ± 8.3 years, 21 patients male (56.8%). In the evaluation of myocardial perfusion images, no differences were detected between images obtained in the 24-hour E1 arm, and those from 1 (2.0 ± 1.5) hour or 12 (12.6 ± 3.1) hours randomization E2. Mean plasma caffeine level was 0.14 ± 0.17 mg/l in group E1 of the 1-hour arm E2, and 0.13 ± 0.24 mg/l in group (E1) of the 12-hour arm (E2), respectively, compared with 1.97± 0.83 mg/l, in the 1-hour, and 1.51 ± 1.46 mg/l, in the 12-hour (E2) randomized arms (E1 vs. E2: p < 0.001). In the 31 patients (83.7%) with presence of paraeffects, the most frequent were: atypical precordial pain, tiredness and pain on cervical area. There were no differences in the absolute and relative frequency in the occurrence of paraeffects between groups. However, with respect to the intensity of pareffects, a subjective analysis was undertaken, comparing symptoms of two exams. which resulted in 22 patients (59.4%) ranking the randomized study a lot better, or better than the 24-hour one. The systemic blood pressure and the heart rate behavior also did not reveal any significant differences between groups. Conclusions: The results may imply that the use of caffeine ingested 2 hours prior to the CPM with adenosine was effective and safe, for despite the change in maximal vasodilator response achieved, manifested by better tolerance of the examination with less time in the absence of caffeine in the diet, did not change the final result of the CPM

D-Frutose-1,6-difosfato (F1,6BP), um intermediário altamente energético da via glicolítica, é descrito na literatura como portador de diversas atividades farmacológicas, contudo seu mecanismo de ação ainda não fora esclarecido. Dessa forma, a possível atividade anti-inflamatória da F1,6BP sobre diferentes modelos de inflamação e sua via de ação em camundongos foram averiguadas com enfoque na inibição da produção de citocinas e na elevação dos níveis endógenos de adenosina. A hipernocicepção mecânica foi avaliada por método eletrônico de pressão crescente em patas de camundongos, o ensaio cinéticocolorimétrico de mieloperoxidase (MPO) foi utilizado na avaliação da migração leucocitária para o tecido subcutâneo plantar, e a performance motora dos animais foi determinada pelo teste rota-rod. A quantificação de citocinas foi realizada por ELISA, enquanto a quantificação de adenosina foi obtida em cromatografia líquida de alta eficiência (CLAE) após validação laboratorial da metodologia segundo normas protocoladas pela ANVISA. O pré-tratamento de camundongos com F1,6BP reduziu a hipernocicepção induzida por injeção intraplantar de carragenina (45%), TNF-a (40%), IL-1B (46%), KC (33%), prostaglandina E2 (41%) e dopamina (55%). O tratamento com F1,6BP, no entanto, não alterou a produção de citocinas induzidas por carragenina (TNF-a, IL-1B e KC) e nem interferiu com a migração leucocitária para a região desafiada. Por outro lado, o efeito antinociceptivo da F1,6BP foi prevenido por tratamento sistêmico e local com antagonista de receptores A1 de adenosina (DPCPX) e o tratamento com adenosina apresentou efeitos similares os do tratamento com F1,6BP, sugerindo que o efeito da F1,6BP é mediado pela ação periférica da adenosina sobre receptores A1. Endossando isso, foi constatado por meio de cromatografia líquida de alta eficiência um aumento na concentração plasmática de adenosina em camundongos após administração de F1,6BP. Por conseguinte, a via de ação da F1,6BP parece ser dependente da produção de adenosina, mas não da modulação na produção de citocinas hipernociceptivas. A adenosina atua, então, perifericamente em receptores A1 inibindo a hipernocicepção, e a evidência farmacológica de que ela medeia a atividade da F1,6BP através dessa ação sobre receptores A1 foi corroborada por resultados in vivo que demonstram aumento dos níveis de adenosina decorrente da administração de F1,6BP. Em vista disso, esses resultados insinuam um possível potencial terapêutico da F1,6BP em reduzir a dor inflamatória. / D-Fructose-1,6-bisphosphate (F1,6BP), a high-energy glycolytic pathway intermediate, is reported to have a many pharmacologically effect, but its underlying mechanism of action in inflammation is incompletely understood. In this study, the aim was to examine the function of F1,6BP on cytokines and adenosine. Then, the possible F1,6BP anti-inflammatory activities in different models of inflammation and its mechanism of action in mice were addressed focusing inhibition of cytokine production or adenosine production enhancement. Mechanical hypernociception (decrease in the nociceptive threshold of animals) was evaluated by the electronic pressure meter test in mice, the myeloperoxidase (MPO) kineticcolorimetric assay was used to evaluate the leukocyte migration to the subcutaneous plantar tissue of mice hind paw, and mice motor performance were evaluated on the rota-rod test. The cytokines levels were measured by ELISA. Adenosine levels were determined by high performance liquid chromatography and this experimental procedure was validated according to ANVISA for this purpose. The pretreatment of mice with F1,6BP reduced the hypernociception induced by intraplantar injection of carrageenan (45%), TNF (40%), IL-1 (46%), KC (33%), prostaglandin E2 (41%) and dopamine (55%). However, FBP treatment did not alter carrageenin-induced cytokines (TNF-, IL-1 and KC) production or the leukocyte migration to the subcutaneous plantar tissue of mice hind paw. On the other hand, the antinociceptive effect of F1,6BP was prevented by systemic and local treatment with an adenosine A1 receptor antagonist (DPCPX) and adenosine treatment presented similar effect of F1,6BP, suggesting that F1,6BP effect is mediated by peripheral adenosine acting on A1 receptors. In agreement, the present work determined by high performance liquid chromatography that D-Fructose-1,6-bisphosphate administration increased the adenosine endogenous levels in the mice plasma. Therefore, F1,6BP mechanism of action seems dependent on adenosine production but not on modulation of hypernociceptive cytokine production. In turn, adenosine acts peripherally on A1 receptor inhibiting hypernociception. The pharmacological evidence that adenosine through activation of adenosine A1 receptor mediates the antinociceptive action of F1,6BP was supported by the finding that in vivo administration of F1,6BP increases the levels of adenosine in the blood samples. Thus, suggesting the treatment with F1,6BP as a possible therapeutic approach to reduce inflammatory pain.

Abstract Adenosine receptors are heterotrimeric guanine nucleotide-binding (G protein)-coupled receptors (GPCRs) that mediate the effects of the endogenous agonist adenosine. The adenosine A3 receptor (A3R) is the least explored among the four human adenosine receptor subtype members (A1, A2A, A2B and A3) and it is implicated in both neuroprotective and neurodegenerative effects. During the course of this work, the production of the recombinant human A3R in yeast and insect cells was evaluated and heteromerization between the human adenosine A2A receptor (A2AR) and the dopamine D2 receptor (D2R) was studied. A3R with carboxyl-terminal GFP tag was expressed in the yeast Saccharomyces cerevisiae upto 15 mg per litre of culture. Another yeast Pichia pastoris increased the expression up to 108 mg/L of the same receptor when grown in bioreactors. Despite the very high expression levels, purification of A3R from both yeasts was a daunting task, as the aggregation of the receptor could not be averted. In this study, insect cells have been found out to be more suitable host for A3R expression: 10µg of the monomeric A3R could be purified from one liter of insect cell culture. For successful crystallization thermostability of the A3R was to be improved. This work has demonstrated that insertion of T4L, a fusion protein, in the third intracellular loop of A3R increased the thermostability of the receptor by 10&#176;C. As a next step, the combination of point mutations based on alanine-scanning mutagenesis and a fusion protein approach could be useful to stabilize and further crystallize the A3R. This work has demonstrated that the amounts of A3R expressed in insect cells and the final yield of the receptor isolated by affinity purifications, forms a good basis for the beginning of biochemical characterization Receptor heteromerization is a mechanism used by GPCRs to diversify their signaling properties and functions. The human A2AR and D2R heteromers exist in the GABAergic enkephalinergic neurons. The domains responsible for forming intermolecular contacts were purified from Escherichia coli (E. coli). Using biochemical/biophysical techniques such as native-PAGE and mass spectrometry, It was validated that purified carboxyl-terminus of the A2AR and the 3rd intracellular loop of D2R form heterodimers. The investigation of purified calmodulin protein binding to the 3rd intracellular loop of D2R showed that the protein-protein interactions are calcium dependent. / Tiivistelmä Adenosiinireseptorit kuuluvat G-proteiinikytkeiset reseptorit (GPCR:t) proteiiniperheeseen. Adenosiinireseptorit välittävät endogeenisen ligandinsa adenosiinin vaikutuksia solukalvolta solunsisäisiin signaalijärjestelmiin. Adenosiini A3 reseptori (A3R) on adenosiinireseptorien neljästä alatyypistä (A1, A2A, A2B ja A3) vähiten tutkittu. Aikaisempien tutkimusten perusteella A3 reseptori yhdistetään sekä hermosoluja suojaaviin että rappeuttaviin tapahtumiin. Tässä työssä arvioitiin sekä ihmisen rekombinantti-A3R:n tuottumista hiiva- ja hyönteissoluissa että tutkittiin ihmisen adenosiini A2A reseptorin (A2AR) ja dopamiini D2 reseptorin (D2R) heteromerisoitumista. Rekombinantti A3 reseptori- vihreä fluoresoiva proteiini (GFP) fuusioproteiinia tuotettiin Saccharomyces cerevisiae -hiivassa 15 mg litrassa kasvatusliuosta. Pichia pastoris -hiivakanta taas kasvatti saman reseptorin tuottumista aina 108 mg/l saakka, kun tuotto tehtiin bioreaktorissa. Hyvin korkeasta tuottotasosta huolimattaA3R:n puhdistus hiivasta oli ylitsepääsemätön tehtävä, sillä reseptorin saostumista ei voinut välttää. Työssä havaittiin, että hyönteissolut sopivat paremmin A3R:n tuottoon: noin 10 µg monomeerista A3R:a voitiin puhdistaa litran hyönteissoluviljelmästä. Reseptorin stabiilisuuden lisääminen helpottaa reseptorin biokemiallista ja biofysikaalista karakterisointia. Tässä työssä osoitettiin, että T4L-proteiinin lisääminen A3R:n kolmannen solunsisäisen silmukan paikalle lisää reseptorin lämpöstabiilisuutta 10 &#176;C. Jatkotutkimuksissa voitaisiin käyttää alaniiniskannausmutageneesiin perustuvien pistemutaatioiden ja fuusioproteiinin yhdistelmää A3R:n lisästabilointiin ja kiteytykseen. Tämän työn perusteella määrät, joilla A3R tuottuu hyönteissoluissa ja jotka saadaan eristettyä affiniteettipuhdistuksilla, muodostavat hyvän perustan proteiinin biokemialliselle karakterisoinnille. Reseptorin heteromerisoituminen on GPCR:en käyttämä mekanismi signalointiominaisuuksien ja toimintojen monipuolistamiseksi. Ihmisessä A2AR ja D2R heteromeereja on GABAergisissä enkefalinergisissä hermosoluissa. Molekyylien välisiin kontakteihin osallistuvat domeenit puhdistettiin Escherichia coli (E. coli) -bakteerista. Biokemiallisia ja biofysikaalisia tekniikoita kuten natiivi-PAGE:a ja massaspektrometriaa käyttäen vahvistettiin, että puhdistettu A2AR:n karboksiterminaalinen osa ja D2R:n kolmas solunsisäinen silmukka muodostavat heterodimeereja. Myös tutkittaessa puhdistetun kalmoduliini-proteiinin sitoutumista D2R:n kolmanteen solunsisäiseen silmukkaan osoitettiin proteiini-proteiini -vuorovaikutuksen olevan kalsiumista riippuvainen.

Les nucléotides, et tout particulièrement l’ATP, sont capables de moduler la fonction de l’un des principaux acteurs de la réponse immunitaire à savoir les cellules dendritiques (DC). Les DC expriment à leur surface de nombreux récepteurs P2X et P2Y dont le P2Y11, couplé à la voie de l’AMP cyclique (AMPc) et impliqué dans l’immunomodulation. L’ATP est capable, par son action sur le P2Y11, d’induire une semi-maturation des DC caractérisée entre autre par une diminution de la sécrétion d’IL-12 et une augmentation de la sécrétion d’IL-10. De plus, des données antérieures obtenues au laboratoire montrent que l’ATP confère également des propriétés immunosuppressives aux DC en stimulant l’expression de la thrombospondine-1 (TSP-1) et de l’indoléamine-2,3-dioxygénase (IDO).<p><p>Dans ce contexte, notre projet visait à établir un profil d’expression génique en réponse à l’ATP dans des DC humaines issues de monocytes (MoDC) afin d’avoir une vue globale de l’action de l’ATP sur les DC. Dans un premier temps, nous avons donc réalisé une étude cinétique comparant les profils d’expression génique en réponse à l’ATPγS, un agoniste plus stable que l’ATP, et à la prostaglandine E2 (PGE2), un activateur de l’AMPc induisant une semi-maturation des DC, par la technique de microarray. L’analyse de ces profils a mis en évidence une action précoce et large de l’ATPγS sur les MoDC. Un grand nombre de régulations obtenues ont confirmé les effets déjà connus de l’ATP sur les DC. Par ailleurs, nous avons confirmé par différentes techniques plusieurs nouvelles cibles de l’ATP impliquées dans l’inflammation et la réponse immunitaire (ex. CSF-1, NRP-1, VEGF).<p><p>En analysant plus en détail ces profils, nous avons observés la régulation de plusieurs gènes dont VEGF, AREG, EREG et HB-EGF, intervenant dans les processus d’angiogenèse et de tumorigenèse. Parmi ceux-ci, le gène AREG codant pour l’amphiréguline, un ligand de l’EGF récepteur (EGFR) était le gène le plus régulé dans notre profil microarray. Pour la première fois, nous avons démontré que les DC traitées à l’ATPγS en présence de LPS constituaient une importante source d’amphiréguline capable de stimuler la croissance de cellules musculaires lisses et de cellules tumorales LLC (Lewis Lung Carcinoma) in vitro. <p>Parallèlement, nous avons étudié l’implication des cellules dendritiques traitées à l’ATPγS sur la croissance tumorale in vivo. Pour ce faire, nous avons coinjecté, à des souris C57 black/6, des cellules tumorales LLC avec des surnageants issus de BMDC traitées au LPS ou au LPS+ATPγS. De cette façon, nous avons mis en évidence que des surnageants issus de BMDC traitées au LPS+ATPγS induisaient une augmentation significative de la masse tumorale par rapport aux surnageants issus de BMDC traités au LPS seul. Au moyen d’un anticorps bloquant anti-amphiréguline, nous avons démontré que cette augmentation de la masse tumorale était due à l’importante sécrétion d’amphiréguline par les BMDC traitées au LPS+ATPγS. De plus, nous avons observé une augmentation du nombre de vaisseaux positifs pour l’α-SMA, un des marqueurs des cellules musculaires lisses, dans les tumeurs issues de la coinjection de cellules LLC avec des surnageants de BMDC traitées au LPS+ATPγS. Pour finir, nous avons montré que les DC au sein des tumeurs LLC expriment non seulement le récepteur EGFR mais également l’amphiréguline. Ces différents résultats observés mettent en avant l’importance de l’ATP extracellulaire dans la croissance tumorale par son action sur les DC. <p> / Doctorat en Sciences biomédicales et pharmaceutiques / info:eu-repo/semantics/nonPublished

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / Diabetes mellitus (DM) is a metabolic disorder of multiple etiology characterized by chronic hyperglycemia resulting from deficiency of production and / or insulin action. This state of hyperglycemia may cause a variety of cardiovascular, renal, neurological and eye complications. Adenosine deaminase (ADA), ecto-5 'nucleotidase (5'NT) and Acetylcholinesterase (AChE) are important enzymes responsible for regulating the levels of adenosine (ado) and acetylcholine (ACh) respectively, and changes in their activities have been demonstrated in various diseases, including Diabetes. Syzygium cumini is a plant mostly used for the treatment of DM and presents hypoglycemic, anti-inflammatory, antipyretic and antioxidants properties. The aim of this study was to verify the effect of aqueous leaf extract of Syzygium cumini (ASc) in 100 and 200μg/mL concentrations, in vitro, on enzymes 5'NT in platelets, ADA in erythrocytes and platelets and AChE in erythrocytes, as well as on parameters of oxidative stress in samples of Type 2 diabetic patients. The results showed an increase in the activity of ADA and 5'NT in platelets from diabetic (n=30) compared to the control group (n=17), as well as in the levels of thiobarbituric acid reactive species (TBARS). ASc at concentrations of 100 and 200 μg / mL was able to reverse these effects. Correlations between 5 NT activity and triglycerides levels, as well as between ADA activity and glucose levels were also found in this work. An increase in the activity of enzymes ADA and AChE in erythrocytes of patients with type 2 diabetes (n=30) compared to the control group (n=20), as well as changes in parameters of oxidative stress, such as increased levels of TBARS and decrease in superoxide dismutase (SOD) activity and levels of non-protein sulfhydryl groups (NP-SH) in these cells also were observed. Likewise, ASc reduced the ADA and AChE activities and lipid peroxidation, and reversed the effect of the evaluated oxidative parameters. Still, there were found significant positive correlations between levels of Vitamin C and protein sulfhydryl groups (P-SH), plasma glucose and levels of P-SH and NP-SH, levels of P-SH and ADA activity, besides a negative correlation between TBARS and NP-SH levels. Therefore, it is possible to suggest that the ASc was able to promote a compensatory response in the platelet function and may act in the maintenance of adenosine levels and vasodilatation and thereby, contributes to the maintenance of the vascular integrity which is important in the hyperglycemic state. It is also possible that ASc might modulate the levels of ACh, interfering with oxidative stress and / or inflammatory processes from the diabetic state. So far, these results confirm the already known antioxidants properties of Syzygium cumini, which makes this compound present significant effects on the cellular metabolism, as well as the reduction and prevention of cardiovascular disease risk in diabetics. / O Diabetes mellitus (DM) é uma disfunção metabólica de múltipla etiologia caracterizado por hiperglicemia crônica resultante da deficiência da produção e/ou ação da insulina. Esse estado de hiperglicemia pode provocar uma série de complicações cardiovasculares, renais, neurológicas e oculares. A adenosina deaminase (ADA), ecto-5 nucleotidase (5 NT) e acetilcolinesterase (AChE) são importantes enzimas responsáveis por regular os níveis de adenosina (ado) e acetilcolina (ACh), respectivamente, e alterações nas suas atividades têm sido demonstradas em várias doenças, incluindo o DM. O Syzygium cumini é uma das plantas mais utilizadas no tratamento do DM, apresenta propriedades hipoglicêmicas, antiinflamatórias, antipiréticas e antioxidantes. O objetivo deste estudo foi verificar o efeito do extrato aquoso das folhas de Syzygium cumini (ASc), nas concentrações de 100 e 200 μg/mL, in vitro, sobre as enzimas 5 NT em plaquetas, ADA em eritrócitos e plaquetas e AChE em eritrócitos, bem como sobre parâmetros de estresse oxidativo em amostras de pacientes diabéticos Tipo 2. Os resultados demonstraram um aumento na atividade das enzimas ADA e 5 NT em plaquetas de diabéticos (n=30) em relação ao grupo controle (n=17), assim como nos níveis de espécies reativas ao ácido tiobarbitúrico (TBARS). ASc, nas concentrações de 100 e 200 μg/mL foi capaz de reverter estes efeitos. Correlações entre a atividade da 5 NT e os níveis de triglicerídeos, bem como entre a atividade da ADA e os níveis de glicose também foram encontradas nesse trabalho. Um aumento na atividade das enzimas ADA e AChE em eritrócitos de pacientes com Diabetes tipo 2 (n=30) em relação ao grupo controle (n=20), além de alterações nos parâmetros de estresse oxidativo, como aumento nos níveis de TBARS e redução na atividade da enzima Superóxido Dismutase (SOD) e nos níveis de grupamentos sulfidrílicos não protéicos (NP-SH) nessas células também foram observados. Igualmente, ASc reduziu a atividade das enzimas ADA e AChE e a lipoperoxidação, e reverteu o efeito dos parâmetros oxidantes avaliados. Ainda foram encontradas correlações positivas significativas entre os níveis de Vitamina C e grupamentos sulfidrílicos protéicos (P-SH), glicose plasmática e níveis de P-SH e NP-SH, níveis de P-SH e atividade da ADA, além de correlação negativa entre os níveis de TBARS e NP-SH. Portanto, é possível sugerir que o ASc foi capaz de promover uma resposta compensatória na função plaquetária, podendo atuar na manutenção dos níveis de adenosina e na vasodilatação e, assim, contribuindo para a manutenção da integridade vascular importante no estado hiperglicêmico, tendo em vista o papel cardioprotetor exercido pela mesma. Também é possível que ASc possa modular os níveis de ACh, interferindo no estresse oxidativo e/ou nos processos inflamatórios provenientes do estado diabético. Ao mesmo tempo esses resultados corroboram com as já conhecidas propriedades antioxidantes de Syzygium cumini, o que faz com que esse composto apresente efeitos significativos no metabolismo celular, bem como na redução e prevenção do risco de doença cardiovascular em diabéticos.

Pythiosis is a disease caused by the oomycete Pythium insidiosum that affects horses, cattle, sheep, cats and humans, and occurs in tropical, subtropical and temperate regions. In horses the lesions are characterized by ulcerative eosinophilic granulomas. Most drugs are ineffective against this pathogen and immunotherapy has shown promise in the regression of the disease, even without the complete elucidation of the immune mechanisms involved. The purinergic system via adenine nucleotides (ATP and ADP) and its derivated nucleoside (adenosine), plays an important role in modulating the immune and inflammatory responses. Once released by cells, nucleotides interact with specific receptors and their extracellular concentrations are controlled by a group of ecto-enzymes, among which are ENTPDase (ecto-nucleoside triphosphate diphosphohydrolase) and ADA (adenosine deaminase). Taking into account the importance of immunotherapy in the treatment of pythiosis and a possible involvement of purinergic signaling in the immune response, the activities of E-NTPDase and E-ADA were evaluated in lymphocytes of rabbits with experimental pythiosis. For disease induction, zoospores were inoculated, subcutaneously, in the lateral region of the torax of each rabbit. These animals were evaluated weekly and the nodular area (cm2) developed was determined after 28 days of inoculation. Animals with experimental pythiosis, confirmed by enzyme immunoassay and the development of characteristic lesions, were treated with immunotherapy, whereas the ratio between the enzymatic activity in lymphopcytes and the consequent triggered immune response was investigated. Animals that did not develop lesions and those from the control group showed the same pattern of ectoenzymatic activity. E-NTPDase activity in lymphocytes of rabbits with experimental pythiosis was significantly higher (p<0,001) in relation to ATP hydrolysis (about 100%) and may be related to decreased (p<0,05) serum ATP (54,04%), when compared to the control group. After immunotherapeutic treatment, the activity of E-NTPDase showed similar values to those observed on the day of inoculation. Moreover, rabbits with experimental pythiosis showed a significant decrease (p<0,01) in the activity of E-ADA (82,36%), and this would lead to a significant increase in the extracellular concentration of adenosine (2,51 times), in relation to the control group (p<0,01). After immunotherapy, this group of animals showed a significant increase in the activity of E-ADA (78,62%) (p<0,01). Through this study, it can be observed that an increased activity of E-ADA, during pythiosis, leads to extracellular regulation of ATP and adenosine concentration. As a result, low levels of extracellular ATP could activate P2Y receptors, while high levels of extracellular adenosine may activate A2A and/or A2B receptors, triggering a TH2 response, responsible for the tissue damage generated by infection. After immunotherapy, it can be observed an inversion in the behaviour of the enzymatic activities, stimulating a TH1 response in the host. The switch from a TH2 response, responsible for the injuries that occur on pythiosis, to a TH1 response, is the most accepted hypothesis to explain the healing properties of immunotherapy. Thus, it is suggested the involvement of purinergic system in the pattern of immune response that occurs during pythiosis and after immunotherapy. / A pitiose é uma doença causada pelo oomiceto Pythium insidiosum que acomete equinos, bovinos, ovinos, felinos e seres humanos, e ocorre em regiões tropicais, subtropicais e temperadas. Em equinos as lesões são caracterizadas por granulomas eosinofílicos ulcerados. A maioria das drogas antifúngicas é ineficaz contra este patógeno e a imunoterapia tem se mostrado promissora na regressão da doença, mesmo sem a elucidação completa dos mecanismos imunes envolvidos. O sistema purinérgico, através dos nucleotídeos de adenina (ATP e ADP) e seu derivado nucleosídeo (adenosina), desempenha um importante papel na modulação da resposta imune e inflamatória. Uma vez liberados pelas células, os nucleotídeos interagem com receptores específicos e suas concentrações extracelulares são controladas por um grupo de ecto-enzimas, entre as quais estão a E-NTPDase (Ecto-Nucleosídeo Trifosfato Difosfoidrolase) e ADA (adenosina desaminase). Levando-se em conta a importância da imunoterapia no tratamento da pitiose e uma possível participação da sinalização purinérgica na resposta imune, foram avaliadas as atividades das ecto-enzimas NTPDase e ADA em linfócitos de coelhos com pitiose experimental. Para a indução da doença, zoósporos foram inoculados por via subcutânea, na região lateral do tórax, de cada coelho. Os coelhos inoculados foram avaliados semanalmente e a área nodular (cm2) desenvolvida foi determinada após 28 dias da inoculação. Os animais com pitiose experimental, confirmada por teste imunoenzimático e pelo desenvolvimento de lesão característica, foram tratados com imunoterápico, sendo que a relação entre as atividades enzimáticas nos linfócitos e o tipo de resposta imune foi investigada. Os animais que não desenvolveram lesão e os animais do grupo controle mostraram o mesmo padrão de atividade das ectoenzimas. A atividade da E-NTPDase nos linfócitos dos coelhos com pitiose experimental mostrou-se significativamente maior (p<0,001) em relação à hidrólise de ATP (em cerca de 100%), podendo estar relacionada à diminuição (p<0,05) da concentração sérica de ATP (54,04%), quando comparado ao grupo controle. Após o tratamento com o imunoterápico, a atividade da E-NTPDase apresentou valores semelhantes aqueles observados no dia da inoculação. Por outro lado, os coelhos com pitiose experimental apresentaram uma diminuição significativa (p<0,01) na atividade da E-ADA (82,36%), o que levaria a um importante aumento na concentração extracelular de adenosina (2,51 vezes) em relação ao grupo controle (p<0,01). Após a imunoterapia, este grupo de animais apresentou um aumento significativo na atividade da E-ADA (78,62%) (p<0,01). Através deste estudo, podese observar que a atividade aumentada da E-NTPDase e a atividade diminuída da E-ADA, durante a pitiose, levam à regulação da concentração do ATP e da adenosina no meio extracelular. Em conseqüência, baixos níveis extracelulares de ATP poderiam ativar receptores P2Y, enquanto, altos níveis de adenosina poderiam ativar receptores A2A e/ou A2B desencadeando uma resposta TH2, responsável pelos danos teciduais gerados na infecção. Com a imunoterapia, pode-se observar uma inversão no comportamento das atividades enzimáticas, estimulando uma resposta TH1 no hospedeiro. A mudança de uma resposta TH2, responsável pelas lesões que ocorrem na pitiose, para um padrão de resposta TH1, é hipótese mais aceita para explicar as propriedades curativas da imunoterapia. Dessa forma, sugere-se a participação do sistema purinérgico no padrão de resposta imune que ocorre durante a pitiose e após a imunoterapia.

Les biocapteurs sont des moyens d’analyse en plein essor à la fois rapides, sélectifs et peu coûteux applicables à des domaines extrêmement variés (environnement, santé, agroalimentaire,…). Dans ce type d’outil, un élément sensible de nature biologique (anticorps, enzyme, microorganisme, ADN…) doté d’un pouvoir de reconnaissance pour un analyte ou un groupe d’analytes est associé à un transducteur pouvant être de type électrochimique, optique ou thermique.Dans ce travail, nous nous sommes intéressés au développement de trois biocapteurs pour la détection de substances biologiquement actives. Le premier permet la détermination simultanée de l’adénosine triphosphate (ATP) et du glucose par ampérométrie, le deuxième celle de la créatine kinase, et le troisième est un biocapteur conductimétique pour la quantification de l’ATP. Dans les deux premiers biocapteurs, deux enzymes (l’hexokinase et la glucose oxydase) sont immobilisées à la surface de microélectrodes constituées d’un disque de platine. Le troisième biocapteur est basé sur l’immobilisation de l’hexokinase sur des microélectrodes interdigitées en or. L’immobilisation est réalisée dans tous les cas par co-réticulation des enzymes en présence d’albumine de sérum bovin à l’aide de glutaraldehyde. Les caractéristiques analytiques des biocapteurs ont été déterminées et différentes procédures ont été développées pour l’analyse d’échantillons réels. Les biocapteurs ont pu être appliqués avec succès à la quantification de l’ATP, du glucose et de la créatine kinase dans des préparations pharmaceutiques et du sérum sanguin / Biosensors are rapid, selective and inexpensive devices that combine a biological recognition element, the so-called bioreceptor (e.g. enzymes, antibodies, DNA or microorganisms) to a physical transducer (e.g. electrochemical, optical, thermal or piezoelectrical). They can be used to detect one specific analyte or one family of analytes for a wide range of applications (e.g. environment, food, health). In this work, the detection of biologically active substances was targeted. A biosensor system for simultaneous determination of adenosine triphosphate (ATP) and glucose, a biosensor for creatine kinase analysis, and a novel conductometric biosensor for ATP determination were developed. In the first two biosensors, two enzymes (hexokinase and glucose oxidase) were immobilized at the surface of platinum disc microelectrodes for amperometric detection. The third biosensor was based on hexokinase immobilized onto gold interdigitated microelectrodes for conductometric detection. In all cases, the enzymes were co-immobilized with bovine serum albumin by cross-linking using glutaraldehyde. Analytical characteristics of the biosensors were determined and different procedures were developed for real samples analysis. The biosensors could be successfully applied to the determination of ATP, glucose, and creatine kinase in pharmaceutical samples and blood serum

G protein-coupled receptors (GPCRs) are eukaryotic integral membrane proteins that perform transmembrane signal transduction. Due to their pivotal role in a wide range of essential physiological functions GPCRs represent a high proportion of all drug targets. High resolution X-ray structures of GPCRs are however underrepresented in the Protein Data Bank. This is due to their instability in detergent, low expression levels and the presence of misfolded receptors in many heterologous expression systems. The objective of this project was to engineer the angiotensin II type 1 receptor (AT1R), a human GPCR, to make it suitable for structural studies. It was determined that detergentsolubilised AT1R was thermostable with antagonist bound with an apparent Tm of ~45°C, which was sufficiently stable for purification without further thermostabilisation by rational mutagenesis. Two expression systems were then evaluated for large-scale production of AT1R, namely baculovirus-mediated expression in insect cells and mammalian expression in HEK293 cells. Radioligand binding assays showed that only the mammalian system produced sufficient quantities of active AT1R for structural studies. Expression in the mammalian system was further optimised to approximately 6 mg/L. An AT1R-GFP fusion was created to examine membrane localisation using confocal laser scanning microscopy, to assay expression levels, to select highly expressing monoclonal cell lines using fluorescence activated flow cytometry and to develop a fluorescence size-exclusion chromatographybased assay to examine the suitability of 12 different ligands for co-crystallization. AT1R was also engineered to facilitate crystallisation, including C-terminal truncations to remove predicted disordered regions and bacteriophage T4-lysozyme being added to the third intracellular loop to provide additional points of contact for crystallisation, which increased the apparent Tm by approximately 10°C. All modified versions of AT1R were assessed for expression, stability and monodispersity. Additionally a rapid western blotting based assay was developed for the detection of unfolded membrane proteins, which will have wide applicability in the field.

The discovery of cyclic AMP (cAMP), nearly 50 years ago by Sutherland radically altered the appreciation of metabolic regulation. Since then the presence of cAMP and its tremendous physiological impact has been demonstrated in many prokaryotic systems. In fact, virulence mechanisms of several pathogens known today exploit cAMP dependent pathways. Interestingly the genome of Mycobacterium tuberculosis H37Rv, the causative agent of tuberculosis, encodes as many as 16 adenylyl cyclases (enzymes that convert ATP to 3’, 5’-cAMP) and 10 cyclic-nucleotide binding proteins. Recent reports show that bacterial-derived cAMP manipulates host signaling for bacterial survival, suggesting an important role for cAMP in the pathogenesis of M. tuberculosis. A large number of non-pathogenic species of mycobacteria also share and conserve several of these cAMP metabolism genes, suggesting that cAMP is not only important for pathogenesis but also may play a critical physiological role in the genus. The work carried out in this thesis aims at a better understanding of the role of cAMP by studying the adenylyl cyclases and cyclic AMP receptor proteins (CRPs) from Mycobacterium smegmatis, a non-pathogenic member of the genus. Intracellular cAMP levels in a cell are precisely maintained by modulating the activities of the adenylyl cyclases (cAMP synthesising enzymes), the phosphodiesterases (cAMP hydrolysing enzymes) and the secretion machinery, if any. To assess the role of cAMP in mycobacteria, cAMP levels were measured in M. smegmatis during growth and under various stress conditions. The results show that cAMP levels peak at log phase of growth and decline thereafter. Under acidic conditions or on perturbing the cell-wall, cellular cAMP levels are altered, which indicate a possible role of cAMP in stress adaptation. Earlier work in our laboratory has led to the identification of multiple adenylyl cyclases in the mycobacterial genomes. These cyclases are similar in sequence to the mammalian enzymes and several of them have been shown to be active in vitro displaying a diverse range of biochemical properties. The M. smegmatis genome encodes 10 adenylyl cyclase-like genes. In order to understand the role of cAMP in M. smegmatis, individual cyclases were analysed for their biochemical properties and physiological functions. The work presented in this thesis is concerned with the functional characterization of MSMEG_3578 and MSMEG_3780, two of the several adenylyl cyclases from M. smegmatis. MSMEG_3578 encodes for a protein that comprises two transmembrane domains, an extracellular receptor-like domain, a membrane anchoring HAMP domain and an intracellular cyclase domain. The cyclase domain is closely related to mammalian cyclases but lacks the canonical residues that are critical for the catalysis of class III cyclases. Interestingly, the stop codon of this gene overlaps with the start codon of the downstream gene, MSMEG_3579 (a putative cyclic nucleotide gated mechanosensitive ion channel), suggesting a functional link between the two genes. The conservation of this gene pair across the mycobacterial genus indicates the importance of this putative receptor-effector pair in the physiology of mycobacteria. Additionally, microarray analysis by various groups have shown that this gene pair in Mycobacterium tuberculosis is differentially regulated in conditions that mimic stress the bacteria may experience during infection. In order to ascertain the physiological role of MSMEG_3578, a knock-out M. smegmatis strain was generated and tested for growth and cAMP defects. The knock-out strain showed growth and cAMP profiles similar to the wild-type strain. Over-expression of MSMEG_3578 in M. smegmatis resulted in a significant rise in cAMP levels. Interestingly, over-expression of the MSMEG_3578 adenylyl cyclase in E. coli did not lead to an elevation in cAMP levels indicating that other mycobacterial proteins may be required for the activity of MSMEG_3578 in vivo. In agreement with this, the purified adenylyl cyclase domain of MSMEG_3578 was found to be biochemically inactive in vitro. Additionally, the over-expressing strain has altered colony morphology as compared to the wild type strain. Perturbation of cAMP levels by over-expression of other cyclases also leads to a similar colony morphology phenotype, indicating the phenotype to be controlled by cAMP in general rather than by a specific cyclase in the cell. MSMEG_3780 is a highly conserved, biochemically active adenylyl cyclase, speculated to play a house-keeping function in M. smegmatis. Its orthologs from M. tuberculosis (Rv1647) and M. leprae (ML1399) have been biochemically characterized earlier in our laboratory. To unravel the role of this gene in vivo, the ∆MSMEG_3780 strain was tested for growth and cAMP defects under various conditions. The deletion strain did not show any difference in growth rate or morphology when compared to the wild-type strain. However it showed a reduction in intracellular cAMP levels at the log-phase of growth. Reintroduction of the MSMEG_3780 gene in the deletion strain restored cAMP to wild-type levels, thus indicating a crucial role for this adenylyl cyclase in the maintenance of intracellular cAMP levels during logarithmic growth. In order to investigate the regulation of the MSMEG_3780 gene, its promoter activity was tested under various stress-conditions. Acid-stress specifically resulted in the repression of the MSMEG_3780 promoter activity, a condition which also leads to a decrease in cAMP levels in the cells. Further evidence for the susceptibility of the MSMEG_3780 gene to acid-stress was obtained when the ∆MSMEG_3780 strain failed to reduce intracellular cAMP content upon sustained acid-stress conditions. Since Rv1647 shares similar biochemical properties with MSMEG_3780 and can also heterodimerize with the MSMEG_3780 protein in vitro, it was interesting to test whether the M. tuberculosis ortholog could functionally complement MSMEG_3780. To assess this, a complement strain was generated that contained the Rv1647 gene under the control of MSMEG_3780 promoter, integrated into the genome of ∆MSMEG_3780 strain. Rv1647 protein was able to restore the cAMP phenotype seen on acid stress as well as the cAMP levels in the mutant strain at the log phase of growth. This study indicated the role of cAMP and MSMEG_3780 in acid adaptation and also suggested a non-redundancy of adenylyl cyclases in mycobacteria, where different individual cyclases may have unique functions in the cells. Since Rv1647 could complement the cAMP defective phenotype in ∆MSMEG_3780, this suggests functional parallels between the proteins from the two species. Bacterial adaptation to environmental stress is brought about by a rapid change in its gene expression profile. Cyclic AMP plays an important role by binding to and activating a transcriptional factor, cAMP receptor protein or CRP. We have identified two CRPs from M. smegmatis, viz., MSMEG_0539 and MSMEG_6189 that possess high similarity at the amino acid level (78% overall sequence identity). The CRP ortholog from M. tuberculosis, Rv3676 has been characterized structurally, biochemically and functionally earlier. Western blot and RT-PCR analyses showed that CRPs in M. smegmatis were present during all phases of growth. Both the CRPs were cloned, expressed and shown to bind cAMP. Since the DNA binding domains of Rv3676 and the two M. smegmatis CRPs are nearly identical, the CRPs from M. smegmatis were predicted to bind similar target sequences. Interestingly, a CRP site was identified in the promoter of the MSMEG_3780 gene, suggesting a possible feed-forward or feed-back loop, where the enzymatic product of the adenylyl cyclase now governs its own gene expression. We performed Electrophoretic Mobility Gel Shift Assays (EMSAs) with M. smegmatis lysates to show that CRP binds to the MSMEG_3780 promoter at the CRP site. Subsequent Chromatin Immunoprecipitation (ChIP) assays confirmed that CRP binding to the MSMEG_3780 promoter occurred in vivo. To investigate the role of CRP in the regulation of the MSMEG_3780 gene, luciferase reporter assays with the wild-type and CRP site mutant promoters were carried out. Results suggest that CRP regulates the MSMEG_3780 gene under osmotic stress. However, CRP did not play any role in basal expression of MSMEG_3780 during growth. To assess which CRP of the two is functionally linked to the MSMEG_3780 promoter, we carried out a footprint assay with purified CRPs. It was intriguing to note that both the CRPs were in fact able to bind the promoter albeit under different conditions. Whereas MSMEG_6189 bound the promoter both in the presence and absence of cAMP, MSMEG_0539 bound the promoter only in the presence of cAMP. MSMEG_6189 thus deviates from the accepted CRP paradigm that seeks an absolute requirement of cAMP for specific DNA binding. The present study identifies cAMP as an important stress signal in M. smegmatis. Using MSMEG_3780 as a model gene, the role of cAMP in mycobacteria was studied. The two divergent CRPs that were characterized may function and dictate cAMP-mediated and perhaps independent functions in cells. Taken together, our results provide compelling evidence for the important role of cAMP in the general physiology and stress adaptation in M. smegmatis.